Supernus, Inc. (SUPN) stock
SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$28.96−0.08 (-0.28%)
Close on Nov 18, 2026Market cap $3.42BP/E 8.1Yield –
Supernus net income
Net income is the profit left for shareholders after every expense, interest and tax.
Supernus's net income for the twelve months ending Sep 30, 2026 was $450.00M, up 251.6% year over year. For fiscal 2025 it was $210.00M, up 2900.0% from the year before.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.00M | +2900.0% |
| FY2024 | Dec 31, 2024 | $7.00M | – |
| FY2023 | Dec 31, 2023 | -$126.00M | – |
| FY2022 | Dec 31, 2022 | -$42.00M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $137.00M | +226.2% |
| Q2 FY2026 | Jun 30, 2026 | $122.00M | +577.8% |
| Q1 FY2026 | Mar 31, 2026 | $89.00M | +89.4% |
| Q4 FY2025 | Dec 31, 2025 | $102.00M | +385.7% |
| Q3 FY2025 | Sep 30, 2025 | $42.00M | +90.9% |
| Q2 FY2025 | Jun 30, 2025 | $18.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $47.00M | -23.0% |
| Q4 FY2024 | Dec 31, 2024 | $21.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $22.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$97.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $61.00M | – |
See a number that looks wrong?